Samenvatting
Samenvatting AML en MPN
- Vak
- Instelling
Samenvatting van de eerste 10 weken van de minor: Hemato-oncologie (MIN18xx). De onderwerpen Acute myeloïde leukemie en myeloproliferatieve neoplasma worden hier besproken.
[Meer zien]Voorbeeld 2 van de 17 pagina's
Voorbeeld 2 van de 17 pagina's
In winkelwagen
In winkelwagen
Verkoper
Volgen
stalgeie
Voorbeeld van de inhoud
Summary MIN18xx Hemato-oncologyIndex
Acute Myeloid Leukemia...................................................................................................................2
Clinical presentation:.........................................................................................................................2
Prognosis:..........................................................................................................................................7
Future:...............................................................................................................................................7
Flow cytometry.................................................................................................................................9
Markers..............................................................................................................................................9
Myeloproliferative neoplasms.........................................................................................................10
Chronic Myeloid Leukemia...............................................................................................................10
Chronic phase:.................................................................................................................................10
Clinical presentation:...................................................................................................................10
Diagnosis:.....................................................................................................................................10
Accelerated phase:...........................................................................................................................10
Blast phase:......................................................................................................................................10
Treatment: achieve major molecular response BCR-Abl/control gene ratio <0.1%..........................10
BCR-Abl/control gene ratio:.............................................................................................................11
Driver mutations..............................................................................................................................11
JAK2 Mutation..............................................................................................................................11
CALR Mutation.............................................................................................................................11
MPL Mutation..............................................................................................................................11
Additional acquired mutations.....................................................................................................11
Primary myelofibrosis......................................................................................................................12
Clinical presentation:...................................................................................................................12
Prognosis:.....................................................................................................................................12
Treatment:...................................................................................................................................12
Polycythemia Vera...........................................................................................................................12
Clinical presentation:...................................................................................................................12
Diagnostics:..................................................................................................................................13
Treatment:...................................................................................................................................13
Essential thrombocytosis..................................................................................................................13
Clinical presentation:...................................................................................................................13
Prognosis: IPSET score..................................................................................................................13
Treatment:...................................................................................................................................13
Appendix.........................................................................................................................................15
WHO Criteria CML (accelerated phase)............................................................................................15
WHO Criteria PV...............................................................................................................................15
WHO Criteria ET...............................................................................................................................15
WHO Criteria prePMF......................................................................................................................17
WHO Criteria overt PMF..................................................................................................................17
, Acute Myeloid Leukemia
Normal situation: only mature cells can be found in the peripheral blood following normal hematopoiesis 7
million blood cells per second.
Hematopoietic stem cell CD34+/CD38-
Lymphoid progenitor Myeloid progenitor
T cell B cell NK cells Granulocytes
AML: accumulation of immature myeloblasts in the bone marrow takes a lot of space suppressing normal
hematopoiesis. GF-independent proliferation, disturbed apoptosis and inhibited differentiation.
Type I mutation: problem in signal transduction affecting proliferation
Type II mutation: problem in transcription factors affecting differentiation.
AML = type I + type II mutations.
Causes:
Bad luck most of the time: accumulation of somatic mutations during aging
Hereditary diseases: Down syndrome, falconi anemia
Chemicals
Toxic drugs (chemotherapy)
Radiation
Clinical presentation:
Non-specific (general) symptoms: fatigue, fever, night sweats, loss of apetite, malaise.
Anemia, leukopenia, neutropenia, thrombocytopenia
Bleeding (hemorrhages, nose bleeds, menorrhagiableeding that won’t stop)
Gout (rare)
Recurrent infections
EMD (myeloblasts in other organs)
Leukostasis (high viscosity of the blood caused by the high number of leukocytes)
Swelling of spleen and liver
Skin abnormalities (petechia, hematoma, chloroma, erythema nodosum)
Diagnostics: bone marrow and peripheral blood
Blood count
Blood smear: visible blasts, lymphoid or myeloid?
Bone marrow aspiration and biopsy
Morphology (FAB) classification M0 – M7
o M0: Undifferentiated acute myeloblastic leukemia
o M1: AML with minimal maturation
o M2: AML with maturation
o M3: Acute promyelocytic leukemia different treatment arsenic + vitamin A (proven to be
effective)
o M4: Acute myelomonocytic leukemia
o M5: Acute monocytic leukemia
o M6: Acute erythroid leukemia
o M7: Acute megakaryocytic leukemia
o Other classifications: chemotherapy + stem cell transplantation (either autologous or
allogeneic)
Cytochemistry: chemical stains (dyes) only react with a certrain type of cells and then can be visualized
under the microscope.
Cytogenetics: search for structural/numeric abnormalities in the chromosomes via karyotyping or FISH.
Molecular diagnostics: search for translocations and mutations. Contributes to diagnosis, prognosis,
risk stratification, treatment decisions and precision medicine.
o Chromosomal aberrations e.g. translocations (+- 50% of AML): FISH, SNP array, cytogenetics
2
Voordelen van het kopen van samenvattingen bij Stuvia op een rij:
√ Verzekerd van kwaliteit door reviews
Stuvia-klanten hebben meer dan 700.000 samenvattingen beoordeeld. Zo weet je zeker dat je de beste documenten koopt!
Snel en makkelijk kopen
Je betaalt supersnel en eenmalig met iDeal, Bancontact of creditcard voor de samenvatting. Zonder lidmaatschap.
Focus op de essentie
Samenvattingen worden geschreven voor en door anderen. Daarom zijn de samenvattingen altijd betrouwbaar en actueel. Zo kom je snel tot de kern!
Veelgestelde vragen
Wat krijg ik als ik dit document koop?
Je krijgt een PDF, die direct beschikbaar is na je aankoop. Het gekochte document is altijd, overal en oneindig toegankelijk via je profiel.
Tevredenheidsgarantie: hoe werkt dat?
Onze tevredenheidsgarantie zorgt ervoor dat je altijd een studiedocument vindt dat goed bij je past. Je vult een formulier in en onze klantenservice regelt de rest.
Van wie koop ik deze samenvatting?
Stuvia is een marktplaats, je koop dit document dus niet van ons, maar van verkoper stalgeie. Stuvia faciliteert de betaling aan de verkoper.
Zit ik meteen vast aan een abonnement?
Nee, je koopt alleen deze samenvatting voor €3,49. Je zit daarna nergens aan vast.
Is Stuvia te vertrouwen?
4,6 sterren op Google & Trustpilot (+1000 reviews)
Afgelopen 30 dagen zijn er 71184 samenvattingen verkocht
Opgericht in 2010, al 14 jaar dé plek om samenvattingen te kopen